IVA

Inventiva SA ADR · NASDAQ

Sector Health Technology
Industry Biotechnology
Website inventivapharma.com
Employees(FY) 117
ISIN US46124U1079

Performance

+0.79%

+11.89%

-7.97%

+8.09%

+18.69%

YTD

-33.16%

Profile

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Advanced Technical Analysis

Technical Analysis of IVA 2025-02-03

The stock exhibits a strong bullish sentiment with a Moving Average Score of 83 and a Technical Score of 78, indicating robust upward momentum. However, the Oscillators Score of 56 suggests a more neutral stance, implying that while the overall trend is positive, there may be some short-term fluctuations to watch for.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of IVA

Stock Rank

Recent News & Updates

2024-05-12 14:30
Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor(Globenewswire)
2024-04-03 04:00
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F(Globenewswire)
2024-04-01 02:17
Inventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call Transcript(Insidermonkey)
2024-03-27 15:00
Inventiva announces the nomination of Andre Turenne as Director(Globenewswire)
2024-03-27 04:00
Inventiva reports its 2023 full-year results(Globenewswire)
2024-03-22 04:00
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results(Globenewswire)
2024-03-18 04:00
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D(Globenewswire)
2024-03-13 04:00
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D(Globenewswire)
2024-03-07 03:00
Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed(Globenewswire)
2024-02-15 16:46
Inventiva pauses phase 3 MASH study over patient's raised liver enzymes(Fiercebiotech)
2024-02-15 03:35
Inventiva reports preliminary 2023 fiscal year financial Information and provides an update on its clinical trial NATiV3(Globenewswire)
2024-01-24 03:15
Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux(Globenewswire)
2024-01-10 03:00
Inventiva draws down the second tranche of 25 million under existing Finance Contract with the European Investment Bank(Globenewswire)
2023-12-20 03:00
Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program(Globenewswire)
2023-12-04 03:05
Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH(Globenewswire)
2023-11-21 03:00
Inventiva reports 2023 Third Quarter Financial Information(Globenewswire)
2023-11-06 03:00
Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting 2023(Globenewswire)
2023-10-26 22:01
Roblox upgraded, Bristol Myers downgraded: Wall Street's top analyst calls(Yahoo Finance)
2023-09-28 04:00
Inventiva reports its 2023 first-half financial results and provides a corporate update(Globenewswire)
2023-09-20 04:00
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea(Yahoo Finance)
2023-08-30 13:30
Inventiva announces a financing of approximately 35.7 million from new and existing investors, consisting of a 30.6 million reserved capital increase and a 5.1 million issuance of royalty certificates(Yahoo Finance)
2023-07-27 04:33
Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update(Yahoo Finance)
2023-07-27 04:00
Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update(Yahoo Finance)
2023-06-23 14:00
Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association(Yahoo Finance)
2023-06-13 05:00
Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD(Yahoo Finance)
2023-06-07 14:30
Inventiva and Echosens launch joint initiative to increase NASH awareness and access to screening for at-risk patients(Yahoo Finance)
2023-06-07 04:00
Inventiva announces five scientific presentations at the EASL International Liver Congress 2023(Yahoo Finance)
2023-05-26 04:00
Results of the votes of the Combined Shareholders General Meeting of May 25, 2023(Yahoo Finance)
2023-05-25 04:00
Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China(Yahoo Finance)
2023-05-24 21:50
Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 25 May 2023(Yahoo Finance)

Page 2 of 5

previous next

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.